A broader prioritised matrix combining national mortality, analytical testing, rapid surveillance, treatment, wastewater and official evidence reviews.
Signals assessed12Substances and market presentations
Critical2Nitazenes and Orphines
High priority6Sedatives, ketamine and gabapentinoids
Horizon monitoring4Stimulants, GBL/GHB and Tusi
Expanded coverage
The matrix now includes orphines, ketamine, pregabalin and other gabapentinoids, methamphetamine, synthetic cathinones and GBL/GHB alongside nitazenes, veterinary sedatives, novel benzodiazepines, synthetic cannabinoids and Tusi. A place on the matrix means structured monitoring is warranted; it does not imply equal prevalence or certainty.